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EDITORIAL COMMENT

Myocardial Recovery or
Urgent Transplant
Mutually Exclusive Goals Under the
Current UNOS Allocation System*
Jennifer A. Cowger, MD, MS,a Rebecca Cogswell, MD, MSb

I

t has been 3 years since the introduction of the

dropped from 1.6% to 0.2%. 1 Patients delisted for

revised United Network Organ Sharing (UNOS)

recovery were more likely to have a nonischemic

heart allocation system. More than 50 papers

diagnosis and lower pulmonary arterial pressures

have been published examining wait times and

and were less likely to have implantable cardiac

changes in patient care patterns and outcomes in

deﬁbrillators, consistent with the characteristics of

the old vs new UNOS systems. In the analysis by Top-

patients with acute (recoverable) heart failure as

kara et al 1 in this issue of the Journal, the outcomes of

well as patients who have demonstrated recovery

patients on temporary mechanical circulatory support

on durable left ventricular assist device (LVAD)

(tMCS) listed as UNOS statuses 1 to 2 (current alloca-

support. The authors should be commended for

tion system) vs status 1A (old system) for heart trans-

their contributions, because their ﬁndings highlight

plant were compared. Similar to prior reports,2-5

the important need for providers to identify pa-

patients listed status 1 to 2 in the new UNOS heart

tients with recovery potential and to critically

allocation system had greater use of tMCS, higher

consider the risks and beneﬁts of immediate status

and quicker rates of transplantation, and lower wait-

1-2 transplant listing.

list mortality than patients listed as status 1A under
the old system. 1

There are a few points worth considering, however, when interpreting the results. First, the in-

SEE PAGE 900

The novel results presented by Topkara et al1
are that the frequencies of transplant delisting
for myocardial recovery on tMCS are lower under
the new allocation system. For waitlist candidates
on extracorporeal membrane oxygenation (ECMO)
or nondischargeable biventricular assist devices,
delisting for myocardial recovery decreased from
7.9% under the old system to 1.5% in the new
system. For status 2 patients on tMCS, recovery

tents of the UNOS allocation systems, in general,
are to “increase the number of organs recovered
and the number of transplants performed, and to
ensure patients across the nation have equitable
access to transplant.” 6 Recovery is not an aim of
UNOS transplant listing, and the new system should
not be viewed as “hindering chances of myocardial
recovery in select candidates.” Rather, under the
new policy’s aim to expedite transplant for the
sickest patients, a reduction in the frequency of
delisting because of myocardial recovery in patients
assigned to UNOS statuses 1-2 was completely
foreseeable, appropriate, and in line with the new

*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the

policy’s intent.
Second, although the hazard ratios demonstrate

views of JACC or the American College of Cardiology.

reduced recovery for patients on tMCS under the new

From the aHenry Ford Hospital, Detroit, Michigan, USA; and the bUni-

vs old allocation systems, the absolute number of

versity of Minnesota, Minneapolis, Minnesota, USA.

patients delisted for transplant during the course of

The authors attest they are in compliance with human studies commit-

the entire analysis averaged only 9 candidates per

tees and animal welfare regulations of the authors’ institutions and Food
and Drug Administration guidelines, including patient consent where
appropriate. For more information, visit the Author Center.

year (80 recoveries within 2,925 patients studied over
10 years). In addition, myocardial recovery as deﬁned
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by Topkara et al 1 occurred when candidates were

argue that patients in cardiogenic shock with reliance

delisted for “condition improved, transplant not

on tMCS for organ perfusion will have little room for

needed.” Delisting does not mean that heart function

rapid titration of guideline-directed therapies. He-

normalized, nor does it mean that patients had

modynamic stabilization to allow for medication

favorable outcomes after removal from the waitlist.

titration for recovery takes time.

Outcomes in these delisted patients are presently

Despite the minor study limitations discussed, we

unknowable, because they are not tracked by UNOS.

believe that the data by Topkara et al1 should force

Third, the variability in the types of patients listed

practitioners to pause when it comes to listing acute

in each era may affect the validity of the comparisons

heart failure patients for status 1 to 2 transplant. As

made. Listing patients with recovery potential under

the decision to transplant is a point of no return, we

the old allocation system was likely conducted with a

agree that patients with acute heart failure with

different set of patient considerations and expecta-

characteristics supportive of recovery may be better

tions—expectations that were also heavily inﬂuenced

served by durable LVADs to allow time for clinical

by the different listing requirements and very

evolution of the patient’s acute cardiomyopathy tra-

different considerations for durable LVAD implant

jectory. Unfortunately, there are high costs to this

and anticipated time on the waitlist. For example,

strategy if recovery does not occur, because the

under the previous allocation system, status 1A wait

pathway to transplant from durable LVAD is more

times for patients on extracorporeal membrane

difﬁcult now under the current allocation system.

oxygenation were much longer than in the present

GAPS IN THE FIELD

era (31 days for status 1A vs 5 days for status 1). Differences were also noted in the frequency of
myocarditis diagnoses (3.1% of status 1 vs 7.2% of
status 1A) in the urgent statuses.1 Although it is

This analysis highlights several current knowledge
gaps.

possible that fewer patients had myocarditis in the

 The ﬁeld lacks a high level of evidence for using

new allocation era, it is more likely that practitioner

tMCS over inotropic support in patients listed for

expectations have evolved in response to the new

heart transplant who have early-stage shock.

system, and rather than abandoning recovery at-

 The rarity of recovery within this UNOS analysis,1

tempts, patients with recovery potential in the pre-

other cohort analyses, and for patients on durable

sent UNOS era were either not listed or were listed at

LVAD support leaves the ﬁeld without an ability to

lower urgency statuses to avoid rapid transplant.

accurately identify patients with acute heart fail-

Additionally, it is important to acknowledge that

ure and cardiogenic shock who will achieve sus-

status 1A tMCS patient selection and management

tained myocardial recovery.

assumptions within the subpopulation of patients

 Finally, research within the ﬁeld is hindered by a

with recovery potential may not be transferable to

lack of linkage between the Intermacs, UNOS, and

today’s status 2 patients. Although cardiogenic shock

outside data sources (such as Medicare or insur-

implies patient instability, the literature clearly

ance databases), preventing comparisons of man-

demonstrates marked variability in shock phenotypes

agement strategies (MCS, transplant, recovery)

that goes beyond baseline characteristics and snap-

applied to similar heart failure populations. The

shot hemodynamics, the ﬁndings of which were the

ﬁeld needs to abolish data silos and engage in

impetus behind the SCAI (Society for Cardiovascular

collaborative research efforts across therapeutic

Angiography & Interventions) shock categorizations. 7

offerings.

Thus, it is possible that status 2 patients in the new
UNOS era are of a sicker phenotype than tMCS 1A era
patients. These potential differences in patient phenotypes and management strategies may make inferences on practitioner attempts at myocardial
recovery through a comparison of recovery frequencies between UNOS eras potentially invalid.
Finally, the authors state that “shorter waitlist
times may preclude the use and escalation of neuro-

Filling these knowledge gaps will add muchneeded evidence to team decision making as it relates speciﬁcally to myocardial recovery and (simultaneously) the overall application of advanced heart
failure interventions that offer the best long-term
outcomes for a given patient phenotype.
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